First do no harm: overdiagnosis in Pediatrics.

Arch Argent Pediatr

Magíster en Salud Pública Vicepresidente, Mantenimiento de la Certificación y Calidad. Junta Estadounidense de Pediatría.

Published: December 2018

Many errors can be made in diagnosis: underdiagnosis, misdiagnosis, and overdiagnosis. While underdiagnosis and misdiagnosis are clear errors, in overdiagnosis, a true abnormality is discovered, but detection does not benefit the patient. Harm occurs when patients are further evaluated and treated unnecessarily as a result of making a diagnosis that would never have affected the patient if the diagnosis had not been made. Several phenomena point to potential overdiagnosis: when delayed or missed diagnoses do not result in harm; when there is increased detection of a disease, but no change in the outcome; and when randomized trials show no benefit from the diagnosis. Some might say that there is always benefit in knowing, but the adverse effects of overdiagnosis are well documented. We will need to educate ourselves and our colleagues about the potential for harm from overdiagnosis, and learn how to balance the potential benefit of a diagnosis against the risk of overdiagnosis.

Download full-text PDF

Source
http://dx.doi.org/10.5546/aap.2018.eng.426DOI Listing

Publication Analysis

Top Keywords

harm overdiagnosis
8
underdiagnosis misdiagnosis
8
benefit diagnosis
8
overdiagnosis
6
diagnosis
5
harm
4
overdiagnosis pediatrics
4
pediatrics errors
4
errors diagnosis
4
diagnosis underdiagnosis
4

Similar Publications

Extending breast cancer screening beyond age 45-64 years in China: A cost-effectiveness analysis.

Cancer Lett

January 2025

Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address:

The optimal breast cancer (BC) screening age in China remains uncertain. In this study, we evaluated the benefits, harms, and cost-effectiveness of lowering the screening starting age from 45 to 35 years and extending the stopping age from 64 to 79 years in Chinese women at an average risk of progressing BC. Biennial screening showed a lower incremental cost-effectiveness ratio (ICER) compared to annual screening.

View Article and Find Full Text PDF

Nearly a decade after the National Academy of Medicine released the "Improving Diagnosis in Health Care" report, diagnostic errors remain common, often leading to physical, psychological, emotional, and financial harm. Despite a robust body of research on potential solutions and next steps, the translation of these efforts to patient care has been limited. Improvement initiatives are still narrowly focused on selective themes such as diagnostic stewardship, preventing overdiagnosis, and enhancing clinical reasoning without comprehensively addressing vulnerable systems and processes surrounding diagnosis.

View Article and Find Full Text PDF

Background: Prostate-specific antigen (PSA) testing is not recommended as a population screening measure for prostate cancer. PSA testing is nevertheless widespread and is associated with harm due to false-positive test results, overdiagnosis and economic costs.

Aims: This study sought to document the exposure of patients to PSA testing over a decade in a general medical practice setting.

View Article and Find Full Text PDF

Evaluating progress and accountability for achieving COP26 Health Programme international ambitions for sustainable, low-carbon, resilient health-care systems.

Lancet Planet Health

October 2024

Department of Anesthesiology, Yale School of Medicine, New Haven, CT, USA; Department of Environmental Health Sciences, Yale School of Public Health, New Haven, CT, USA.

Article Synopsis
  • The COP26 Health Programme, launched at the 2021 UN Climate Change Conference, aims to create low-carbon and resilient health systems, with 83 countries committed to the initiative as of May 2024.
  • The analysis highlights significant issues in current monitoring practices, showing that many countries focus on process indicators that don't truly measure progress towards sustainable health-care systems.
  • There is a critical need for better, adaptable indicators that can effectively track health-care outcomes and contribute to climate strategies, ensuring that the COP26 Health Programme achieves its goals without misleading claims.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!